Physician profile
Daniel John Ryan
NPI 1447888094
$9,110.05
in general payments reported to CMS, 2019-2025
22 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.10 · 2021: $929 · 2022: $3,544 · 2023: $3,556 · 2024: $755 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454 · Travel and Lodging: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,453.65 |
| Travel and Lodging | $1,169.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,349.73 | 2021-2025 | Augment Injectable, Variax, Hoffmann |
| Medwest Associates | $1,324.25 | 2022 | |
| Integra Lifesciences Corporation | $701.00 | 2022-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kerecis Limited | $515.39 | 2021-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Acera Surgical, INC. | $415.80 | 2022 | |
| Horizon Therapeutics Plc | $308.18 | 2021-2023 | Krystexxa |
| Smith+Nephew, INC. | $272.00 | 2021-2025 | Grafix Pl, Panta 2, Cadence |
| Depuy Synthes Sales INC. | $238.55 | 2020-2024 | Motoband |
| Organogenesis INC. | $183.08 | 2021-2025 | Puraply Wound Matrix, Cygnus Dual |
| Zimmer Biomet Holdings, INC. | $149.97 | 2021 | |
| Ibsa Pharma INC. | $125.00 | 2023 | Licart |
| Paratek Pharmaceuticals, INC. | $98.36 | 2022 | |
| Sanara Medtech INC. | $78.09 | 2023 | Celleraterx |
| Medline Industries Lp | $76.66 | 2023 | |
| Fusion Orthopedics USA, LLC | $57.70 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lightbody Medical Technologies INC | $51.58 | 2024 | |
| Convatec INC. | $44.08 | 2024 | |
| Treace Medical Concepts, INC. | $35.87 | 2024 | |
| Averitas Pharma INC. | $28.21 | 2023 | Qutenza |
| Amgen INC. | $23.24 | 2024 | Krystexxa |
| Surgenex LLC | $20.05 | 2025 | Renograft, Ardeograft, Surgraft |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.26 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.